Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
9 Tips for Avoiding Tax Season Cyber Scams 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Major pharmaceutical companies in South Korea, including Cho Kun Dang, GC Pharma, and Daewoong Pharmaceutical Co., are releasing their own drug for treating COVID-19. The made in Korea medicines are said to be hitting the market soon.
With these South Korean pharma companies’ entrance to the COVID-19 treatment market, Korean drugs for treating the virus just increased to four. This is because Celltrion is also releasing its COVID-19 treatment called the CT-P59 after going through phases of clinical trials.
Drug companies announce successful results of coronavirus treatments
Celltrion was already approved for emergency use in December. This means that South Korea’s Ministry of Food and Drug Safety has given its permission for doctors are to administer Celltrion’s COVID-19 antibody treatment to patients with life-threatening conditions even while clinical trials for CT-P59 or Regdanvimab are still ongoing.
Now, a day after Celltrion reported positive top-line efficacy and safety data from its global Phase II/III clinical trial on Jan. 13, Chong Kun Dang pharma also showed encouraging results from its own phase 2 trial for COVID-19 treatment called Nafamostat.
This drug has been tested on more than 100 volunteers in Russia. At least 36 high-risk patients were given the drug, and Nafamostat reportedly showed 61.1% clinical improvement. Plus, just like what Celltrion claimed, Chong Kun Dang also stated that its COVID-19 treatment drug shortened the recovery time of patients by at least four days.
Chong Kun Dang further suggests that Nafamostat can help prevent death in seriously-ill COVID-19 patients. As per the Korea Herald, the pharmaceutical firm is now trying to get approval for its phase 3 trials and emergency use.
Emergency-use drug application for the pharma companies
Celltrion was already approved for emergency use, and Ching Kung Dang sent its application for approval. On the other hand, GC Pharma and Daewoong are also expected to apply soon.
For GC Pharma, it will get approval for its blood plasma-derived COVID-19 treatment called GC5131A. It has completed its phase 2 trial with 60 volunteers, and data results are expected to come out soon. This company’s drug is meant to treat patients of serious COVID-19 cases.
Daewoong is now in phase 3 trial, but although its phase 2 tests returned good results, it did not show the effects they were hoping for. It will be applying for emergency use authorization for its Camostat drug that is meant for treating mild and moderate cases.
Finally, all of these companies still need to show more results from phase 3 trials so they can be approved and eventually released into the market.
